Carregant...

IL-2, the next best thing in chronic GVHD therapy?

In this issue of Blood, Koreth et al have reported that interleukin-2 (IL-2) is effective in chronic graft-versus-host disease (cGVHD) patients who had failed up to two prior lines of therapy.(1)

Guardat en:
Dades bibliogràfiques
Publicat a:Blood
Autors principals: Curtis, Lauren M., Pavletic, Steven Z.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2016
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4937357/
https://ncbi.nlm.nih.gov/pubmed/27389542
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2016-05-711796
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!